Filing Details

Accession Number:
0001562180-20-003451
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-07 16:25:11
Reporting Period:
2020-05-05
Accepted Time:
2020-05-07 16:25:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434418 Constellation Pharmaceuticals Inc CNST () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1246842 A Mark Goldsmith C/O Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge MA 02142
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-05 2,325 $1.55 145,388 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Acquisiton 2020-05-05 300 $11.50 145,688 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Acquisiton 2020-05-05 520 $7.60 146,208 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Disposition 2020-05-05 3,145 $40.01 143,063 No 4 S Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Acquisiton 2020-05-06 6,813 $1.55 149,876 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Acquisiton 2020-05-06 750 $11.50 150,626 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Acquisiton 2020-05-06 3,900 $7.60 154,526 No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Common Stock Disposition 2020-05-06 11,463 $45.06 143,063 No 4 S Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 S Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 M Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
No 4 S Indirect Owned by Trusts for which Mark A. Goldsmith is a Trustee
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-05-05 2,325 $0.00 2,325 $1.55
Common Stock Stock Option (right to buy) Disposition 2020-05-05 300 $0.00 300 $11.50
Common Stock Stock Option (right to buy) Disposition 2020-05-05 520 $0.00 520 $7.60
Common Stock Stock Option (right to buy) Disposition 2020-05-06 6,813 $0.00 6,813 $1.55
Common Stock Stock Option (right to buy) Disposition 2020-05-06 750 $0.00 750 $11.50
Common Stock Stock Option (right to buy) Disposition 2020-05-06 3,900 $0.00 3,900 $7.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
24,525 2021-03-10 No 4 M Direct
7,875 2028-07-18 No 4 M Direct
17,646 2028-03-07 No 4 M Direct
17,712 2021-03-10 No 4 M Direct
7,125 2028-07-18 No 4 M Direct
13,746 2028-03-07 No 4 M Direct
Footnotes
  1. These trades were made pursuant to a Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $40.00 to $40.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $45.00 to $45.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Shares are fully vested.
  5. This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2021.
  6. This option was granted on March 8, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 8, 2021.
  7. Shares are fully vested.